Vyriad is a pioneering biotechnology company focused on developing innovative cancer treatments. The company engineers targeted, efficient, and stable virus platforms to deliver durable in vivo gene therapies, genome editing, and oncolytic virotherapies. Vyriad's mission is to provide effective and precise therapies for cancer patients through purposeful collaborations and a comprehensive approach that integrates preclinical development, manufacturing, and clinical expertise.
Vyriad has made significant strides in the field of cancer treatment, leveraging advanced viral engineering to create impactful therapeutic solutions. The company's holistic approach has led to successful partnerships and advancements in clinical applications, positioning Vyriad as a leader in the oncolytic virotherapy space. Through its innovative products and collaborative efforts, Vyriad continues to make substantial contributions to the fight against cancer.
